November 7, 2022

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

CLOSURES AND SUSPENSIONS

HEAD & NECK

NRG-HN008: Temporary Closure: November 03, 2022 (Study Memorandum posted on NRG Oncology).

AMENDMENTS

BRAIN

NRG-BN011: Amendment 1, version date: September 13, 2022 (posted on CTSU)

GENITOURINARY

RTOG 0924: Amendment 6, version date: September 28, 2022 (posted on CTSU)

GYNECOLOGIC

NRG-GY018: Amendment 11; version date: September 30, 2022 (posted on CTSU)

NRG-GY022: Amendment 4; version date: September 21, 2022 (posted on CTSU)

HEAD & NECK

NRG-HN001: Amendment 9, version date: October 03, 2022 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Actively Recruiting MALE Patients only. Read More

2. BREAST / GASTROINTESTINAL

NRG-BR003, NRG-BR007, NRG-GI004, NRG-GI005, and NRG-GI008: Memo - Scheduling Protocol Therapy for Non-medical Delays (posted to individual protocol pages on the CTSU website)

3. GYNECOLOGIC

NRG-GY012 and NRG-GY023 – BLOOD PRESSURE CUFF SUPPLY IS VERY LIMITED - Please be advised that VWR has a very limited supply of blood pressure cuffs at present. Please check your supplies on site for any overlooked cuffs prior to ordering. Thank you for your cooperation.  

GOG-0210: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

GOG-0225: To provide the most accurate and reliable assessment possible, sites are asked to answer any outstanding queries and update the Overall Survival status and last contact date for all patients enrolled on GOG-0225 no later than Friday, December 2, 2022. This trial utilizes the SEDES EDC system for form entry. If site personnel need access to SEDES for this study, please contact support@nrgoncology.org. SEDES can be accessed via the GOG Web menu.

4. HEAD & NECK

NRG-HN010: The Spanish-translated consent form and CIRB approval of the form are available on CTSU.

5. LUNG

REGISTER TODAY! Information Webinar for the NRG-LU006 Clinical Trial

NRG Oncology will be hosting an informational webinar regarding the NRG-LU006 clinical trial on Thursday, November 17, 2022, from 7-8 pm ET. This webinar is open to all who register. This webinar is specifically aimed to engage thoracic surgeons and will address surgical concerns, barriers to enrollment and answer protocol-specific questions.

The Phase III randomized NRG-LU006 study is currently active and enrolling patients with malignant pleural mesothelioma (MPM). The trial is designed to compare adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) combined with pleurectomy/decortication surgery and systemic therapy to surgery and systemic therapy alone. The goal of this study is to see if the addition of adjuvant hemithoracic IMPRINT can improve overall survival for patients with MPM.

The webinar will be led by Andreas Rimner, MD, the Director of Thoracic Radiation Oncology Research at Memorial Sloan Cancer Kettering Center and NRG-LU006 Principal Investigator. Presentations will be followed by a question and answer segment with the study team.

Register here: https://bit.ly/NRG-LU006-Webinar-Registration

6. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, November 9, 2022.

DRUG SAFETY AND INVESTIGATOR’S BROCHURE (IB) UPDATES

Drug Safety and Investigator’s Brochure updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website. Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

NRG Oncology Patient Advocate Committee: Call for Candidates

Help improve cancer clinical trials and the lives of cancer patients by becoming a patient advocate. We are currently recruiting volunteers for the Patient Advocate Committee’s membership with assignments to the following committees: Gastrointestinal Colorectal Cancer, Gastrointestinal Non-Colorectal Cancer, and Gynecologic Cancer. More information about the NRG Patient Advocate role, requirements, and benefits is available on the NRG Oncology Website.

NRG Cancer Care Delivery Research (CCDR) Committee Hosts Webinar on Artificial Intelligence

The NRG CCDR Committee will be hosting a webinar to introduce participants to the use of artificial intelligence (AI) and its role in varied cancer care delivery settings. Integration of AI technology into cancer care settings may improve and expedite diagnosis, inform clinical decision making and produce better health outcomes. The presentations will highlight AI’s contribution to radiation oncology, medical oncology and palliative care. This session will held on November 10, 2022, 12 – 1:30pmEST and co-lead by Dr. Julian Hong of the University of California, San Francisco and Dr. Michael Gensheimer of Stanford Health Care. Please view the flyer here.

Click here to register for the webinar

Reminder: Veterans Day Closure Information

Please note the following NRG Oncology locations will be closed on Friday, November 11, 2022, in observance of Veterans Day: Philadelphia East Operations Center, Buffalo SDMC, and the Biospecimen Bank in San Francisco. All other locations will be open during regular business hours on that day. More information about these closures is posted on the CTSU website.

PUBLICATIONS REMINDERS

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Liang Y, Lee K, Bovi JA, Palmer JD, Brown PD, Gondi V, Tomé WA, Benzinger TLS, Mehta MP, Li XA. Deep Learning-Based Automatic Detection of Brain Metastases in Heterogenous Multi-Institutional Magnetic Resonance Imaging Sets: An Exploratory Analysis of NRG-CC001. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):529-536. doi: 10.1016/j.ijrobp.2022.06.081. Epub 2022 Jul 2. PMID: 35787927. Read more

Michikawa C, Torres-Saavedra P, Silver N, Harari PM, Kies MS, Rosenthal DI, Le Q, Jordan RC, Duose DY, Mallampati S, Trivedi S, Luthra R, Wistuba II, Osman AA, Lichtarge O, Foote RL, Parvathaneni U, Hayes DN, Pickering CR, Myers JN. Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234. Adv Radiat Oncol. 2022 Nov-Dec;7(6):100989. doi: 10.1016/j.adro.2022.100989. Epub 2022 May 18.  Read more

Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, Hunter GK, Crocker IR, Chao ST, Pugh SL, Armstrong TS. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neurooncol Adv. 2022 Oct 22;4(1):vdac152. doi: 10.1093/noajnl/vdac152. PMID: 36299794; PMCID: PMC9587696. Read more

Please note the following upcoming meeting and abstract submission deadline dates

UPCOMING MEETINGS

Radiological Society of North America (RSNA); Nov 27-Dec 1, 2022; Chicago, IL

San Antonio Breast Cancer Symposium (SABCS); Dec 6-10, 2022; San Antonio, TX

Society for Neuro-Oncology (SNO); Nov 16-20, 2022; Tampa, FL

Society of Urologic Oncology (SUO); Nov 30-Dec 2, 2022; San Diego, CA

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 14-19, 2023; Orlando, FL; meeting submission deadline Nov 17, 2022, 11:59 EST; LBA Jan 12, 2023

American Head & Neck Society (AHNS); July 8-12, 2023; Montreal, QC Canada; due to publications committee Nov 14, 2022; meeting submission deadline Dec 2, 2022, 5 pm EST

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; Jan 19-21, 2023; San Francisco, CA; LBA Nov 15, 2022, NOON EST

American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; Feb 16-18, 2023; San Francisco, CA; LBA Dec 13, 2022, NOON EST

ESMO Gynaecological Cancers Annual Congress 2023; Feb 23-24, 2023; Barcelona, Spain; due to publications committee Nov 15, 2022; meeting submission deadline Nov 29, 2022, TIP 9 pm CET (CntEurTime)

European Society for Radiotherapy and Oncology (ESTRO); May 12-16, 2023; Vienna, Austria; LBA Jan 18, 2023, 9 pm EST

Society for Clinical Trials (SCT); May 21-24, 2023; Baltimore, MD; Contributed Oral & Poster Presentations meeting submission deadline Nov 14, 2022

Society of Surgical Oncology (SSO 2023); Surgical Cancer Care; Mar 22-25, 2023; Boston, MA; LBA Dec 9, 2022

St. Gallen Breast Cancer Conference (SG-BCC); Mar 15-18, 2023; Vienna, Austria; due to publications committee Dec 2, 2022; meeting submission deadline Dec 16, 2022